Clinical Fellowships
This grant funds U.S. academic institutions to train physicians in multidisciplinary clinical care and research focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis).
Funder: Alnylam Pharmaceuticals
Due Dates (Anticipated): August 2026 (Clinical Fellowships submission deadline, projected)
Funding Amounts: Up to $95,000 per one-year clinical fellowship; funding covers salary and fellow benefits only.
Summary: Supports U.S. academic institutions in training physicians in ATTR Amyloidosis through multidisciplinary clinical fellowship programs.
Key Information: Applicants must be ACGME-accredited U.S. institutions with active Cardiology Fellowship Programs.
Description
Alnylam Pharmaceuticals offers Clinical Fellowship Grants to support educational clinical programs at U.S. healthcare academic organizations, specifically focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The goal is to advance the training of physicians in the diagnosis, treatment, and research of ATTR, fostering multidisciplinary collaboration for early recognition, optimized treatment pathways, and the translation of emerging science into high-quality, patient-centered care. Funding is provided to institutions (not individuals) and is intended solely for the salary and benefits of clinical fellows.
